The acquisition is intended to offer the innovative therapy of Orbus' R stent design and the potentially revolutionary Genous bio-engineered surface technology, which is currently being evaluated in a clinical trial. Financial terms of the agreement were not disclosed.
The acquisition is the outcome of a long working relationship between the two companies. Neich Medical was previously Orbus' distributor for Asia Pacific and manufactures the delivery system for Orbus' R stent. The combined company will be called Orbus Neich
Orbus' development of a coronary R stent design, uses biotechnology to provide vascular health by targeting, accelerated healing. The R stent Coronary SDS is indicated for treatment of atherosclerotic or restenotic lesions
Specifically, drug-eluting stents have revolutionised the treatment of blocked arteries by using chemical coatings to prevent reclogging of the blood vessels,
It works by taking antibody-coated stents, which opens up blocked blood vessels, stimulating the body's own repair system to heal itself, preventing reclogging and blood clots.